

Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Michael C. d'Emden^{1,2} · Alicia J. Jenkins⁴ · Liping Li³ · Diana Zannino³ ·
Kristy P. Mann³ · James D. Best⁴ · Bronwyn G. A. Stuckey⁵ · Kris Park⁶ ·
Juha Saltevo⁷ · Anthony C. Keech³ · on behalf of the FIELD Study Investigators

Published online: 18 July 2015
© Springer-Verlag Berlin Heidelberg 2015

Erratum to: Diabetologia
DOI 10.1007/s00125-014-3344-3

The authors wish to point out two typographical errors in Fig. 3. In the fenofibrate arm, the proportion of men who had a stroke was 3.8% (not 13.8%) and the proportion of men who underwent revascularisation was 9.9% (not 39.9%). The plotted hazard ratios are correct.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-014-3344-3>.

✉ Anthony C. Keech
fieldtrial@ctc.usyd.edu.au

¹ Endocrine Research Unit, Royal Brisbane Hospital, Brisbane, QLD, Australia

² Department of Medicine, University of Queensland, Brisbane, QLD, Australia

³ National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia

⁴ Department of Medicine, University of Melbourne, Melbourne, VIC, Australia

⁵ Keogh Institute for Medical Research and Sir Charles Gairdner Hospital, Perth, WA, Australia

⁶ Nepean Hospital, Sydney, NSW, Australia

⁷ Department of Medicine, Central Finland Central Hospital, Jyväskylä, Finland